Business Description
Cardiff Oncology Inc
NAICS : 325414
SIC : 2836
ISIN : US8972384080
Description
Cardiff Oncology Inc a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical program in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC").
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 34.2 | |||||
| Equity-to-Asset | 0.79 | |||||
| Debt-to-Equity | 0.03 | |||||
| Debt-to-EBITDA | -0.04 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | -1.05 | |||||
| Beneish M-Score | -1.77 | |||||
| WACC vs ROIC | ||||||
Growth Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -15.1 | |||||
| 3-Year EBITDA Growth Rate | -3.8 | |||||
| 3-Year EPS without NRI Growth Rate | 4.5 | |||||
| 3-Year FCF Growth Rate | 3.9 | |||||
| 3-Year Book Growth Rate | -23.5 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | -8.54 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | -36.26 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 73.08 | |||||
| 9-Day RSI | 68.44 | |||||
| 14-Day RSI | 64.42 | |||||
| 3-1 Month Momentum % | 41.27 | |||||
| 6-1 Month Momentum % | 5.26 | |||||
| 12-1 Month Momentum % | 139.73 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 4.74 | |||||
| Quick Ratio | 4.74 | |||||
| Cash Ratio | 4.6 | |||||
| Days Sales Outstanding | 206.39 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -6.7 | |||||
| Shareholder Yield % | 0.3 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -6735.99 | |||||
| Net Margin % | -6238.17 | |||||
| FCF Margin % | -5022.78 | |||||
| ROE % | -69.27 | |||||
| ROA % | -57.6 | |||||
| ROIC % | -684.89 | |||||
| 3-Year ROIIC % | -682.55 | |||||
| ROC (Joel Greenblatt) % | -1692.6 | |||||
| ROCE % | -73.27 |
GF Value Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 217.52 | |||||
| PB Ratio | 3.43 | |||||
| Price-to-Tangible-Book | 3.45 | |||||
| EV-to-EBIT | -2.88 | |||||
| EV-to-EBITDA | -2.9 | |||||
| EV-to-Revenue | 193.77 | |||||
| EV-to-Forward-Revenue | 131.89 | |||||
| EV-to-FCF | -3.96 | |||||
| Price-to-GF-Value | 1.35 | |||||
| Price-to-Median-PS-Value | 1.21 | |||||
| Price-to-Net-Current-Asset-Value | 3.71 | |||||
| Price-to-Net-Cash | 3.83 | |||||
| Earnings Yield (Greenblatt) % | -34.74 | |||||
| FCF Yield % | -18.28 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Cardiff Oncology Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 0.632 | ||
| EPS (TTM) (€) | -0.862 | ||
| Beta | 2.68 | ||
| 3-Year Sharpe Ratio | 0.25 | ||
| 3-Year Sortino Ratio | 0.63 | ||
| Volatility % | 210.99 | ||
| 14-Day RSI | 64.42 | ||
| 14-Day ATR (€) | 0.294423 | ||
| 20-Day SMA (€) | 2.51225 | ||
| 12-1 Month Momentum % | 139.73 | ||
| 52-Week Range (€) | 1.14 - 5.59 | ||
| Shares Outstanding (Mil) | 51.13 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Cardiff Oncology Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Cardiff Oncology Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Cardiff Oncology Inc Frequently Asked Questions
What is Cardiff Oncology Inc(FRA:XE7C)'s stock price today?
The current price of FRA:XE7C is €3.49. The 52 week high of FRA:XE7C is €5.59 and 52 week low is €1.14.
When is next earnings date of Cardiff Oncology Inc(FRA:XE7C)?
The next earnings date of Cardiff Oncology Inc(FRA:XE7C) is 2025-02-28 Est..
Does Cardiff Oncology Inc(FRA:XE7C) pay dividends? If so, how much?
Cardiff Oncology Inc(FRA:XE7C) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers